Evaluation of the Generic Drug User Fee Act (GDUFA) Program for Fiscal Years 2013-2022

Area of Science:

• Pharmaceutical Policy
• Drug Regulation
• Generic Drug Development

Background:

• The Generic Drug User Fees Act (GDUFA) was established to expedite generic drug approvals.
• GDUFA I (FY 2013-2017) and GDUFA II (FY 2018-2022) represent two authorization periods for this act.
• Evaluating the impact of GDUFA's regulatory initiatives is crucial for understanding generic drug market dynamics.

Purpose of the Study:

• To assess the effectiveness of regulatory initiatives under GDUFA I and GDUFA II.
• To analyze trends in Abbreviated New Drug Application (ANDA) withdrawals and first-cycle approvals.
• To understand the impact of GDUFA on generic drug approval timelines and outcomes.

Main Methods:

• Analysis of ANDA approval data from the Drugs @ FDA database (2013-2022).
• Comparison of key metrics between GDUFA I and GDUFA II periods.
• Inclusion of factors such as approval time, dosage form, route of administration, indication, and market status.

Main Results:

• Generic drug approvals increased by over 40% in GDUFA II compared to GDUFA I.
• Withdrawn applications saw a rise of over 120% in GDUFA II, linked to incentive programs.
• First-cycle approvals doubled between GDUFA I and GDUFA II, indicating improved application quality and review efficiency.

Conclusions:

• GDUFA has demonstrably enhanced the efficiency and effectiveness of the generic drug approval process.
• Incentivized withdrawal of inadequate applications contributed to higher first-cycle approval rates.
• Despite pandemic-related disruptions, GDUFA has positively impacted generic drug accessibility.